Aldeyra has enrolled the first patient in a phase 3 clinical trial of ADX-2191 for the prevention of recurrent retinal detachment due to proliferative vitreoretinopathy, according to a press release.
The two-part, multicenter, randomized, controlled, adaptive, phase 3 GUARD trial is evaluating the efficacy of ADX-2191 (intravitreal methotrexate) vs. standard of care.
“PVR is a very serious retinal disease for which there is no effective treatment,” Dean Eliott, MD, Stelios Evangelos Gragoudas Professor of Ophthalmology at Harvard Medical School and director of the retina service at
Uncategorized